Abstract
A randomized controlled trial involving 13 institutions in Japan was conducted in order to compare the efficacy of tegafur plus mitomycin C (MMC) (Regimen A) and UFT (a combination of uracil and tegafur at a molar ratio of 4 to 1) plus MMC (Regimen B) for patients with advanced gastric cancer, who had not received any prior cancer chemotherapy. Regimen A (tegafur+MMC) consisted of 5 mg of MMC/m2/week given intravenously, and 500 mg of tegafur/m2/day given orally. Regimen B consisted of the same schedule of MMC and 375 mg of UFT/m2/day given orally. One hundred and eighty‐six patients with primary gastric cancer were entered; 183 were eligible and 3 were ineligible for the study. A total of 169 were evaluable for efficacy of the treatment, including 90 patients with Regimen A and 79 with Regimen B. A response rate of 7.8% (7/90 cases) for Regimen A and one of 25.3% (20/79 cases) for Regimen B were obtained, indicating a significantly higher response rate for Regimen B according to the Criteria for Evaluating Efficacy of Chemotherapy /Radiation Therapy in the Treatment of Gastric Cancer (P= 0.004), Regarding side effects, no marked differences in either severity or incidence were observed between the two groups. The group assigned to Regimen B showed a significant survival advantage after adjustment for major prognostic factors using a proportional hazards model (P=0.0398). Moreover, a close correlation of antitumor effect and survival duration was found when the above criteria were used.
Keywords: Randomized study, Tegafur, Tegafur and uracil, MMC, Gastric cancer
Full Text
The Full Text of this article is available as a PDF (413.4 KB).
REFERENCES
- 1. ) Fujii , S. , Ikenaka , K. , Fukushima , M. and Shirasaka , T.Effect of uracil and its derivatives on antitumor activity of 5 ‐fluorouracil and 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil . Gann , 69 , 763 – 772 ( 1978. ). [PubMed] [Google Scholar]
- 2. ) Fujii , S. , Kitano , S. , Ikenaka , K. and Shirasaka , T.Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1‐ (2 ‐tetrahydrofuryl)‐ 5 ‐fluorouracil and level of 5‐fluorouracil in rodents . Gann , 70 , 209 – 214 ( 1979. ). [PubMed] [Google Scholar]
- 3. ) Ogawa , M.An overview of chemotherapy for advanced gastric cancer . In“Diagnosis and Treatment of Upper Gastrointestinal Tumors ”, ed. Friedman M. , Ogawa M. and Kisner D. , pp. 357 – 369 ( 1981. ). Excerpta Medica; , Amsterdam . [Google Scholar]
- 4. ) Kurihara , M. , Shirakabe , H. , Izumi , T. , Miyasaka , K. , Maruyama , T. , Sasaki , Y. , Kobayashi , S. and Kamano , T.X‐ray and endoscopy in the evaluation of gastric cancer chemotherapy . In “ Diagnosis and Treatment of Upper Gastrointestinal Tumors ”, ed. Friedman M. , Ogawa M. and Kisner D. , pp. 428 – 449 ( 1981. ). Excerpta Medica; , Amsterdam . [Google Scholar]
- 5. ) Suga , S. , Kimura , K. , Yoshida , Y. , Horiuchi , T. and Yokoyama , Y.UFTM chemotherapy for gastric cancer: effectiveness and comparison of survival between UFTM and surgical treatment in patients with Borrmann type 4 gastric cancer . In “ Fluoropyrimidines in Cancer Therapy ”, ed. Kimura K. , Fujii S. , Ogawa M. , Bodey G. B. and Alberto P. , pp. 311 – 319 ( 1984. ). Excerpta Medica; , Amsterdam . [Google Scholar]
- 6. ) Goto , Y. , Toyota , T. , Asaki , S. , Kikuchi , T. , Koizumi , M. , Ohkubo , T. , Nomura , N. , Mochizuki , F. , Taima , T. , Miura , K. , Sakurada , H. , Shoji , T. , Nakano , N. , Saito , H. , Okano , T. , Shimizu , H. and Fukuo , A.Randomized controlled study of treatment with UFT‐MMC or UFT‐ACR for advanced gastric cancer . Jpn. J. Cancer Chemother. , 16 , 2227 – 2233 ( 1989. )( in Japanese ). [PubMed] [Google Scholar]
- 7. ) Kurihara , M. , Miyasaka , K. , Izumi , T. , Maruyama , T. , Sasaki , Y. , Kamano , T. and Yasui , A.Evaluation of cancer chemotherapy on gastric cancer by X‐ray and endoscopy . Proc. 13th Int. Congr. Chemother. , pp. 282/10 – 15 ( 1983. ).
- 8. ) Suga , S. , Kimura , K. , Yokoyama , Y. , Isobe , K. , Yoshida , Y. , Takada , T. , Sato , A. , Kuwabara , T. and Iwase , H.Studies on the designing of chemotherapy for gastric cancer in man, based on the tumor tissue concentration of anticancer agents , Gastroenterol. Jpn. , 17 , 295 – 300 ( 1982. ). [DOI] [PubMed] [Google Scholar]
- 9. ) Japanese Research Society for Gastric Cancer , Criteria for Evaluating Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer . “ The General Rules for the Gastric Cancer Study ”, 11th Edition , pp. 102 – 105 ( 1985. ). Kanehara Shuppan; , Tokyo ( in Japanese ). [Google Scholar]
- 10. ) Cox , D. R.Regression models and life tables . J. R. Stat. Soc. Ser. B , 34 , 187 – 220 ( 1972. ). [Google Scholar]
- 11. ) Kurihara , M.Indication and prognostic factors . In “ Chemotherapy of Gastric Cancer ”, ed. Kurihara M. and Nakajima T. , pp. 85 – 87 ( 1981. ). Shinkooigaku Shuppan; , Tokyo ( in Japanese ). [Google Scholar]
- 12. ) Macdonald , J. S. , Wolley , P. , Smythe , T. , Ueno , W. , Hoth , D. and Schein , P. S.5‐Fluorouracil, adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer . Cancer , 44 , 42 – 47 ( 1979. ). [DOI] [PubMed] [Google Scholar]
- 13. ) Moertel , C. G. and Lavin , P. T.Phase II‐III chemotherapy studies in advanced gastric cancer . Cancer Treat. Rep. , 63 , 1863 – 1869 ( 1979. ). [PubMed] [Google Scholar]
- 14. ) Wagener , D. , Yap , S. , Wobbes , T. , Burghouts , J. , Dam , F. , Hillen , H. , Hoogendoorn , G. , Scheerder , H. and Vegt , S.Phase II trial of 5‐fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer . Cancer Chemother. Pharmacol , 15 , 86 – 87 ( 1985. ). [DOI] [PubMed] [Google Scholar]
- 15. ) Moertel , C. G. , Rubin , J. , O'Connell , M. , Schutt , A. and Wieand , H.A phase II study of combined 5‐fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas . J. Clin. Oncol. , 4 , 1053 – 1057 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 16. ) Preusser , P. , Wilke , H. and Achterrath , W.Phase II studie mit Etoposid, Adriamycin, Gisplatin (EAP) Beim Primar inoperablen, metastasierten Magen Karzinom . Tumor Diag. Ther. , 8 , 43 – 48 ( 1987. ). [Google Scholar]
- 17. ) Romond , E. H. and Macdonald , J. S.Chemotherapy of gastric cancer . In “ Gastric Cancer ”, ed. Douglass H. O., Jr. , pp. 205 – 220 ( 1988. ). Churchill Livingstone; , New York . [Google Scholar]
- 18. ) Arbuck , S. , Silk , Y. , Douglass , H. , Nava , H. , Rustum , Y. and Milliron , S.A phase II trial of 5‐fluorouracil, doxorubicin, mitomycin C and leucovorin in advanced gastric carcinoma . Cancer , 65 , 2442 – 2445 ( 1990. ). [DOI] [PubMed] [Google Scholar]
- 19. ) Kurihara , M. and Izumi , T.Chemotherapy of solid tumors – evaluation of effects on gastric cancer . Jpn. J. Cancer Clin. , 26 , 652 – 658 ( 1980. ) ( in Japanese ). [Google Scholar]
- 20. ) Kimura , K. , Konda , C. , Kashiwada , N. , Mikuni , M. , Shimoyama , M. , Kitahara , T. , Kurihara , M. and Inagaki , J.Chemotherapy of abdominal malignant tumors . Naika , 19 , 1314 – 1320 ( 1967. )( in Japanese ). [PubMed] [Google Scholar]
- 21. ) Japanese Research Society for Gastric Cancer , Criteria for Evaluating Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer . “ The General Rules for the Gastric Cancer Study ”, 11th Edition , p. 46 ( 1985. ). Kanehara Shuppan; , Tokyo ( in Japanese ). [Google Scholar]